Overview

Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Status:
Terminated

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

Proof-of Concept, Open-Label, Two-Stage Study without Direct Individual Benefit The proposed study design consists of two treatment periods and one treatment arm. Treatment Period 1 involves the administration of RBV monotherapy for a period of 8 weeks and Treatment Period 2 involves administration of up to 16 weeks combination therapy with RBV plus HCQ.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BioLineRx, Ltd.

Treatments:

Hydroxychloroquine
Ribavirin